{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:02:46Z","timestamp":1788368566285,"version":"build-2803163510"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To comparatively evaluate the efficacy and safety of induction therapies in solid organ transplantation (SOT) using a Bayesian network meta-analysis (NMA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Randomized controlled trials (RCTs) assessing induction therapies were systematically identified across major databases (up to November 20, 2024). The screening, data extraction, and risk of bias (ROB) assessment were independently conducted by two reviewers through standardized tools. Bayesian NMA synthesized outcomes, including rejection, graft\/overall survival, and infection rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty-eight RCTs (9,626 patients) evaluating 12 therapies were included. Surface Under the Cumulative Ranking Area (SUCRA) probabilities identified alemtuzumab as the most effective agent for reducing rejection rates (93.9%), followed by antilymphocyte globulin (ALG, 87.0%) and belimumab (77.0%). For graft survival, OKT3 ranked highest (87.9%), with subsequent superiority for ALG (83.5%) and alemtuzumab (75.6%). Basiliximab demonstrated the highest overall survival benefit (88.0%), outperforming rabbit antithymocyte globulin (rATG, 82.1%) and inolimomab (70.3%). Belimumab showed the greatest infection risk reduction (94.4%), surpassing alemtuzumab (80.0%) and basiliximab (74.5%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Alemtuzumab emerged as the optimal therapy for minimizing rejection, while OKT3 and basiliximab were superior for graft and overall survival, respectively. Belimumab exhibited the strongest potential for reducing incidence of infection. These findings highlight therapy-specific advantages for optimizing SOT outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/myprospero<\/jats:uri>, identifier CRD42025634120.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1625710","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T04:10:15Z","timestamp":1752466215000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative efficacy and safety of induction therapy in solid organ transplantation: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Junjie","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2022.01.002","article-title":"Adaptive immune cell responses as therapeutic targets in antibody-mediated organ rejection","volume":"28","author":"Louis","year":"2022","journal-title":"Trends Mol Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"JCO2400857","DOI":"10.1200\/JCO.24.00857","article-title":"Liver transplantation for hepatocellular carcinoma: an expanding cornerstone of care in the era of immunotherapy","volume":"43","author":"Magyar","year":"2024","journal-title":"JCO"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/anae.15037","article-title":"Optimisation of the organ donor and effects on transplanted organs: a narrative review on current practice and future directions","volume":"75","author":"Bera","year":"2020","journal-title":"Anaesthesia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2024.110800","article-title":"Updates in induction immunosuppression regimens for intestinal transplantation","volume":"85","author":"Paulo Guzman","year":"2024","journal-title":"Hum Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2024.100900","article-title":"Non-adherence to immunosuppressive medications in kidney transplant recipients- a systematic scoping review","volume":"39","author":"Corr","year":"2025","journal-title":"Transplant Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1451907","article-title":"Network meta-analysis of pharmacological treatment for antibody-mediated rejection after organ transplantation","volume":"15","author":"Sun","year":"2024","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01270.x","article-title":"Immunosuppression: evolution in practice and trends, 1994\u20132004","volume":"6","author":"Meier-Kriesche","year":"2006","journal-title":"Am J Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006750.pub2","article-title":"Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients","author":"Karpe","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181b67725","article-title":"Five hundred intestinal and multivisceral transplantations at a single center","volume":"250","author":"Abu-Elmagd","year":"2009","journal-title":"Ann Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/lt.23826","article-title":"Antibody-mediated rejection in liver transplantation: Current controversies and future directions","volume":"20","author":"Taner","year":"2014","journal-title":"Liver Transpl"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.746889","article-title":"Utilization of treg cells in solid organ\u00a0transplantation","volume":"13","author":"Juneja","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200610183608","article-title":"Immunosuppression in liver transplantation: state of the art and future perspectives","volume":"26","author":"Nedredal","year":"2020","journal-title":"Curr Pharm Des"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jclinepi.2019.10.011","article-title":"Excluding non-English publications from evidence-syntheses did not change conclusions: a meta-epidemiological study","volume":"118","author":"Nussbaumer-Streit","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13092","article-title":"ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients","volume":"15","author":"Crepin","year":"2015","journal-title":"Am J Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cells11020243","article-title":"Developing monoclonal antibodies for immunohistochemistry","volume":"11","author":"Cordell","year":"2022","journal-title":"Cells"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2014.230","article-title":"Induction of chimerism and immune tolerance using belatacept","volume":"11","author":"Carney","year":"2015","journal-title":"Nat\u00a0Rev Nephrol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021752","article-title":"Treg therapy for the induction of immune tolerance in transplantation\u2014not lost in translation","volume":"24","author":"Pilat","year":"2023","journal-title":"IJMS"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004822","article-title":"Chronic active antibody-mediated rejection: opportunity to determine the role of interleukin-6 blockade","volume":"108","author":"Berger","year":"2024","journal-title":"Transplantation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40262-017-0573-x","article-title":"Review of the clinical pharmacokinetics and pharmacodynamics of alemtuzumab and its use in kidney transplantation","volume":"57","author":"van der Zwan","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01332","article-title":"Comparison of alemtuzumab and anti-thymocyte globulin treatment for acute kidney allograft rejection","volume":"11","author":"van der Zwan","year":"2020","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.864545","article-title":"Induction strategies in lung transplantation: alemtuzumab vs. Basiliximab a single-center experience","volume":"13","author":"Furukawa","year":"2022","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation","volume":"364","author":"Hanaway","year":"2011","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12824","article-title":"Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study","volume":"14","author":"Jaksch","year":"2014","journal-title":"Am J Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016070768","article-title":"Comparing outcomes between antibody induction therapies in kidney transplantation","volume":"28","author":"Koyawala","year":"2017","journal-title":"JASN"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2025.102832","article-title":"Identification of non-virologic risk factors for lymphoma after the first year of kidney transplant in adults: A retrospective analysis","volume":"97","author":"Santos","year":"2025","journal-title":"Cancer Epidemiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0804-2","article-title":"Treatment and unmet needs in steroid-refractory acute graft-versus-host disease","volume":"34","author":"Malard","year":"2020","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814288","article-title":"Impact of induction\u00a0immunosuppressants on T lymphocyte subsets after kidney transplantation: A prospective observational study with focus on anti-thymocyte globulin and basiliximab induction therapies","volume":"24","author":"Kim","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.716559","article-title":"CD4+CD25+CD127-Foxp3+ and CD8+CD28- tregs in renal transplant recipients: phenotypic patterns, association with immunosuppressive drugs, and interaction with effector CD8+ T cells and CD19+IL-10+ Bregs","volume":"12","author":"Aly","year":"2021","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.idc.2020.02.002","article-title":"Direct T-cell inhibition and agents targeting T-cell migration and chemotaxis","volume":"34","author":"Fern\u00e1ndez-Ruiz","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182888df0","article-title":"Impact of positive flow cytometry crossmatch on outcomes of intestinal\/multivisceral transplantation","volume":"95","author":"Kubal","year":"2013","journal-title":"Transplantation"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15269","article-title":"Long-term survival in visceral transplant recipients in the new era: A single-center experience","volume":"19","author":"Elsabbagh","year":"2019","journal-title":"Am J Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26475","article-title":"Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis","volume":"97","author":"Mo","year":"2022","journal-title":"Am J Hematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.05.020","article-title":"A randomized prospective study comparing anti-T-lymphocyte Igs to basiliximab in highly sensitized kidney transplant patients","volume":"5","author":"Kamar","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004951","article-title":"Basiliximab induction and postoperative steroid-free immunosuppression with tacrolimus in pediatric liver transplantation: A randomized clinical trial","volume":"108","author":"Dong","year":"2024","journal-title":"Transplantation"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2130751","article-title":"Investigational drugs for the treatment of kidney transplant rejection","volume":"31","author":"van Vugt","year":"2022","journal-title":"Expert Opin Investigational Drugs"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14013","article-title":"Prospective analyses of circulating B cell subsets in ABO-compatible and ABO-incompatible kidney transplant recipients","volume":"17","author":"Schl\u00f6\u00dfer","year":"2017","journal-title":"Am J Transplant"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13052","article-title":"Rituximab as induction therapy after renal transplantation: A randomized, double-blind, placebo-controlled study of efficacy and safety","volume":"15","author":"van den Hoogen","year":"2015","journal-title":"Am J Transplant"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13122","article-title":"Transitional B lymphocytes are associated with protection from kidney allograft rejection: A\u00a0prospective study","volume":"15","author":"Shabir","year":"2015","journal-title":"Am J Transplant"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13045","article-title":"Neutralizing BAFF\/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model","volume":"15","author":"Kwun","year":"2015","journal-title":"Am J Transplant"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2021.101465","article-title":"BLyS neutralization results in selective anti-HLA alloantibody depletion without successful desensitization","volume":"69","author":"Agarwal","year":"2021","journal-title":"Transplant Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30984-X","article-title":"Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial","volume":"391","author":"Banham","year":"2018","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001669","article-title":"Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years","volume":"8","author":"Zhang","year":"2022","journal-title":"RMD Open"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1625710\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T04:10:16Z","timestamp":1752466216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1625710\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2025.1625710"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1625710","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"article-number":"1625710"}}